A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma

Activity: Talk or presentationTalk or presentation at a conference


Mini oral presentation in the "Investigational Immunotherapy" session
Period17 Sep 2021
Event titleESMO Congress 2021
Event typeConference
LocationParis, France
Degree of RecognitionInternational